NCT06853496 - Study of a Tankyrase Inhibitor RK-582 for Patients With Unresectable Metastatic Colorectal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 13, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2027

Conditions

Unresectable Colorectal Neoplasm Metastasis

Interventions

DRUG

RK-582

"Dosing Frequency:~Do single dose of RK-582 at the dose level specified for the cohort. Seven days after the first dose, Start repeated daily dose and continue until discontinuation criteria were met.~Dose level per dose:~Dose Level 1: 5 mg BID Dose level 2: 10 mg QD Dose level 3: 20 mg QD Dose level 4: 40 mg QD Dose Level 5: 60 mg QD Dose Level 6: 80 mg QD Dose Level 7: 100 mg QD Dose Level 8: 200 mg QD"

Trial Locations (1)

135-8550

RECRUITING

Cancer Institute Hospital of JFCR, Koto-ku